- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05409378
HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation (RIVAL - AR EFS)
May 29, 2023 updated by: HLT Inc.
To evaluate the safety and performance of The Meridian® TAVR Valve in patients with severe aortic regurgitation who present at high risk for aortic valve replacement surgery.
Study Overview
Status
Withdrawn
Conditions
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Angie Sweson
- Phone Number: 763-416-7517
- Email: Angie.Swenson@hltmedical.com
Study Contact Backup
- Name: Alison Bernhardt
- Phone Number: 763-416-7519
- Email: Alison.Bernhardt@hltmedical.com
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- The Christ Hospital
-
Columbus, Ohio, United States, 43210
- Ohio State University Wexner Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject has evidence of severe aortic regurgitation as assessed by the independent echo core lab according to an integrative multiparametric based on ASE (American Society of Echocardiography) guidelines considering qualitative and quantitative measures.
- Symptoms due to severe aortic regurgitation with a NYHA Functional Classification of II or greater
- Documented aortic valve annular diameter ≥ 21 and ≤ 26 mm (associated perimeter range is 66.0 - 81.7 mm or associated area range of 346 - 531 mm^2) measured by the MSCT Core Lab assessment of pre-procedure imaging
- Documented heart team agreement of high risk for surgical aortic valve replacement (SAVR)
- Geographically available, willing to comply with follow-up and able to provide written informed consent.
Exclusion Criteria:
- Congenital, unicuspid or bicuspid aortic valve which could compromise procedural success
- Severe mitral or tricuspid valve regurgitation
- Moderate to severe mitral stenosis
- Myocardial infarction within the past 30 days*
- Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- Left Ventricular Ejection Fraction (LVEF) < 35%
- Severe pulmonary hypertension with pulmonary systolic pressure greater than two-thirds of systemic pressure
- Hemodynamic instability requiring inotropic drug therapy within the past 30 days
- Untreated clinically significant coronary artery disease requiring revascularization
- Any therapeutic invasive cardiac procedure performed or planned to perform within 30 days of the index procedure, except for PCI which is performed within 7 days prior to the index procedure*
- Presence of significant aortic disease such as atheroma, thrombus, dissection (> 50 mm in diameter or which could be considered high risk for dissection) or aneurysm which precludes safe implant delivery
- Blood dyscrasias defined as leukopenia (White blood cell count < 1,000 cell/mm^3), anemia (hemoglobin < 9.0 g/dL), thrombocytopenia (platelet count < 50,000 cells/mm^3), history of bleeding diathesis or coagulopathy
- Patient ineligible for or refuses blood transfusions
- Unfavorable peripheral vascular anatomy or disease (e.g. severe obstructive calcification, severe tortuosity) that would preclude passage of 18F catheters from the femoral arterial access to the aorta by the MSCT Core Lab assessment of pre-procedure imaging
- Active peptic ulcer or gastrointestinal bleeding requiring hospitalization or transfusion within the past 90 days, that would not allow treatment with the protocol antiplatelet regimen post implant *
Symptoms of carotid or vertebral artery disease (e.g. stroke or transient ischemic attack) within past 6 months, or treatment of carotid stenosis within past two months*
- At the time of procedure, if a subject's medical status has changed since enrollment, the subject shall be re-evaluated for eligibility
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: The HLT® Meridian® TAVR Valve
Transcatheter aortic valve replacement with the HLT Meridian TAVR Valve
|
Aortic valve replacement with the HLT Meridian TAVR Valve to treat aortic regurgitation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality at 30 days
Time Frame: 30-Days
|
The primary safety endpoint is all-cause mortality at 30 days
|
30-Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical Success - A composite endpoint per VARC-3, defined as meeting the following:
Time Frame: Immediately after procedure
|
|
Immediately after procedure
|
Device Success- A composite endpoint per VARC-3, defined as meeting the following:
Time Frame: 30 Days
|
|
30 Days
|
Post-procedural Valve Performance - EOA assessed via Echo
Time Frame: Discharge (or day 7), 30 days, 6, 12, 24, 36, 48 and 60 months
|
• Aortic valve effective orifice area (EOA; cm^2)
|
Discharge (or day 7), 30 days, 6, 12, 24, 36, 48 and 60 months
|
Post-procedural Valve Performance- Aortic Regurgitation (AR) assessed via Echo
Time Frame: Discharge (or day 7), 30 days, 6, 12, 24, 36, 48 and 60 months
|
• Severity of aortic valve regurgitation (AR; graded scale)
|
Discharge (or day 7), 30 days, 6, 12, 24, 36, 48 and 60 months
|
Post-procedural Valve Performance - Aortic Valve Gradient assessed via Echo
Time Frame: Discharge (or day 7), 30 days, 6, 12, 24, 36, 48 and 60 months
|
• Aortic valve gradient (mean and peak; mmHg)
|
Discharge (or day 7), 30 days, 6, 12, 24, 36, 48 and 60 months
|
Adverse Events
Time Frame: Up to 5 years following enrollment
|
All adverse events will be assessed throughout the five (5) year follow up period per VARC-3 definitions
|
Up to 5 years following enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kendra Grubb, MD, Emory University
- Principal Investigator: Charles Davidson, MD, Northwestern University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 8, 2022
Primary Completion (Actual)
January 20, 2023
Study Completion (Actual)
January 20, 2023
Study Registration Dates
First Submitted
May 24, 2022
First Submitted That Met QC Criteria
June 3, 2022
First Posted (Actual)
June 8, 2022
Study Record Updates
Last Update Posted (Actual)
May 31, 2023
Last Update Submitted That Met QC Criteria
May 29, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HLT2101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Regurgitation
-
Imperial College LondonAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)UnknownHeart Valve Diseases | Aortic Valve Insufficiency | Paravalvular Aortic Regurgitation | Regurgitation, AorticNetherlands
-
Centre Chirurgical Marie LannelongueCompletedCardiac Catheterization | Cardiac Valve Disease | Paravalvular Aortic Regurgitation | Paravalvular Mitral Regurgitation
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaTerminatedAortic Regurgitation | Aortic Valve Insufficiency | Regurgitation, Aortic Valve | Aortic Valve | Aortic IncompetenceKorea, Republic of
-
Na Homolce HospitalCentre of Cardiovascular and Transplantation Surgery, Czech Republic; St. Anne... and other collaboratorsRecruitingAortic Valve RegurgitationSerbia, Czechia, Belgium
-
Abbott Medical DevicesEnrolling by invitationParavalvular Aortic RegurgitationUnited States, Spain, Netherlands, Canada, Italy, Poland, United Kingdom
-
Assistance Publique - Hôpitaux de ParisUnknownPure Aortic RegurgitationFrance
-
Genesis Medtech CorporationRecruiting
-
Centre Chirurgical Marie LannelongueEasy-CRFRecruitingQuality of Life | Cardiac Valve Disease | Outcomes | Paravalvular Aortic Regurgitation | Paravalvular Mitral Regurgitation | Paravalvular LeakBelgium, France, Poland, United Kingdom, Czechia, Greece, Italy, Latvia, Lithuania, Mexico, Spain, Turkey
-
UMC UtrechtTerminatedPeriprosthetic Aortic Valve Regurgitation After TAVINetherlands
-
Michele De BonisCompletedAortic Regurgitation | Functional Mitral RegurgitationItaly
Clinical Trials on The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)
-
Ohio State UniversitySpiration, Inc.WithdrawnManagement of BPF (Bronchopleural Fistulae)United States
-
Shanghai NewMed Medical Co., Ltd.Active, not recruiting
-
Shanghai NewMed Medical Co., Ltd.Recruiting
-
Peijia Medical Technology (Suzhou) Co., Ltd.General Hospital of Shenyang Military Region; Shanghai Zhongshan Hospital; China... and other collaboratorsCompleted
-
Braile Biomedica Ind. Com. e Repr. Ltda.Active, not recruiting
-
Nanjing First Hospital, Nanjing Medical UniversityRecruiting
-
Orion Corporation, Orion PharmaCompleted
-
University Clinical Centre of KosovaUniversity of Ljubljana, Faculty of MedicineUnknownType 2 Diabetes Mellitus | PeriodontitisKosovo